SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)

Area of Science:

• Neuro-oncology
• Molecular diagnostics in oncology
• Clinical practice guidelines

Background:

• The 2021 World Health Organization (WHO) classification significantly updated the diagnostic criteria for grade 2 gliomas.
• Isocitrate dehydrogenase (IDH) mutation status is now a critical factor in diagnosing these tumors.
• Grade 2 gliomas, despite slow growth, often require multimodal treatment strategies beyond surgery for optimal prognosis.

Purpose of the Study:

• To provide evidence-based recommendations for the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas.
• To align clinical practice with the latest WHO classification guidelines.
• To enhance the management and improve the prognosis of patients with grade 2 gliomas.

Main Methods:

• Systematic review of the best available evidence.
• Development of clinical recommendations by a multidisciplinary expert panel.
• Focus on integrating molecular diagnostic information (IDH mutation status) into treatment planning.

Main Results:

• The guideline details specific treatment approaches for grade 2 astrocytomas and oligodendrogliomas.
• Recommendations emphasize a multidisciplinary approach, considering tumor biology and patient factors.
• The importance of adjuvant therapies alongside surgical management is highlighted.

Conclusions:

• Adherence to the updated WHO classification and IDH mutation status is crucial for accurate diagnosis and treatment of grade 2 gliomas.
• Multidisciplinary care is essential for optimizing outcomes in patients with these tumors.
• This guideline serves as a valuable resource for clinicians managing grade 2 astrocytomas and oligodendrogliomas.